|
- 品牌：Ansh Labs
- 產(chǎn)地：國外
- 型號：10μL
- 貨號：AL-149
- 發(fā)布日期： 2022-08-25
- 更新日期： 2024-08-12
| 產(chǎn)地 | 國外 |
| 保存條件 | 詳詢 |
| 品牌 | Ansh Labs |
| 貨號 | AL-149 |
| 用途 | 詳詢 |
| 檢測方法 | 詳詢 |
| CAS編號 | |
| 保質(zhì)期 | 詳詢 |
| 適應(yīng)物種 | 詳詢 |
| 檢測限 | 詳詢 |
| 數(shù)量 | 詳詢 |
| 包裝規(guī)格 | 10μL |
| 標(biāo)記物 | 詳詢 |
| 純度 | 詳詢% |
| 樣本 | 詳詢 |
| 應(yīng)用 | 詳詢 |
| 是否進口 | 是 |
Product Description：Insulin-like growth factor binding protein-3 (IGFBP-3) is a 264-amino acid peptide (MW 29 kD) produced by the liver as well as other tissues. It is the most abundant of a group of IGFBPs that transport, and control bioavailability and half-life of insulin-like growth factors (IGF), in particular IGF-I, the major mediator of the anabolic- and growth-promoting effects of growth hormone (GH).The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II, thus prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Most of the IGFBP-3 in plasma is present as the high molecular weight ternary complex, however, small amounts of free IGFBP-3 are also found.
IGFBP-3 also exhibits intrinsic growth-regulating effects that are not yet fully understood, but have evoked interest with regards to a possible role of IGFBP-3 as a prognostic tumor marker. Low IGFBP-3 and IGF-I levels are observed in GH deficiency or GH resistance, also epidemiologic studies suggest that low IGFBP-3 is associated with greater risk of aggressive, metastatic prostate cancers. The elevated serum IGFBP-3 and IGF-I levels indicate a sustained overproduction of GH, or excessive rhGH therapy. Both conditions are associated with generalized organomegaly, hypertension, diabetes, cardiomyopathy, osteoarthritis, and diminished longevity.
The Ansh Labs Intact IGFBP-3 Assay uses an acidification and neutralization method to dissociate Intact IGFBP-3 from all the binding subunits. Intact IGFBP-3 levels are quantified in the extracted samples using a highly sensitive and specific Intact IGFBP-3 ELISA. Total IGFBP-3 levels can be measured using Total IGFBP-3 ELISA (AL-120).
The concentration of bioactive IGF-I, total IGFBP-3 and intact IGFBP-3 in biological fluid can be measured accurately using immunoassay methods (Bioactive IGF-1 ELISA; AL-122, IGF-I inhibition mAb capture and IGF-1 C-terminal mAb) detection; Total IGFBP-3 ELISA; AL-120, C-terminal IGFBP-3 capture and detection mAb; and Intact IGFBP-3 ELISA; AL-149, C-terminal mAb capture and N-terminal mAb detection, respectively). The ratio of total to Intact IGFBP-3 concentration measured in individual subject over time will help normalizes the IGFBP-3 variability between subjects. The immunoassay methods designed for the measurement of bioactive IGF-I, total and Intact IGFBP-3 in patient samples could be of practical value for the diagnosis or prediction of various pathologies including growth abnormalities and cancer.
Regulatory Status：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Packaging：96 well microtiter
Detection：HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter
Dynamic Range：6, 1.7-75 ng/mL
Limit of Detection：0.08 ng/mL
Sample Type：Serum
Assay Time：1.5 hours
Species Reactivity：Bovine, Caprine, Human, Mouse, Rabbit
Shelf Life：24 months
